每日优化剂量利福平治疗结核的安全性、疗效与药代动力学:系统综述与贝叶斯网络荟萃分析
该系统综述与贝叶斯网络荟萃分析纳入19项前瞻性临床研究,3654名参与者中2033人接受高于10 mg/kg/天的利福平剂量。结果显示40 mg/kg/天剂量增加总体和肝脏不良事件风险,而35 mg/kg/天剂量改善第8周痰培养转阴,最优剂量可能在25至35 mg/kg/天之间,但应根据个体或群体水平调整。
要点
- 40 mg/kg/天利福平增加总体不良事件风险(RR 4.8,95% CrI 1.1–25)。
- 40 mg/kg/天利福平增加肝脏不良事件风险(RR 15.00,95% CrI 1.1–58.0)。
- 35 mg/kg/天利福平改善第8周痰培养转阴(RR 1.3,95% CrI 1.1–1.7)。
核心结论
- 利福平最优剂量可能在25至35 mg/kg/天之间,但应根据个体或至少群体水平进行调整。
研究设计与样本
- 系统综述与贝叶斯网络荟萃分析,纳入19项前瞻性临床研究,包括接受利福平剂量高于10 mg/kg/天的成人肺结核和肺外结核患者;3654名参与者中2033人接受高于10 mg/kg/天的利福平剂量。
主要发现
- 40 mg/kg/天剂量增加总体不良事件风险(RR 4.8,95% CrI 1.1–25)和肝脏不良事件风险(RR 15.00,95% CrI 1.1–58.0),其他剂量包括50 mg/kg/天未显示此类增加。
- 35 mg/kg/天剂量改善第8周痰培养转阴(RR 1.3,95% CrI 1.1–1.7)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Higher than standard doses of rifampicin could improve the treatment outcome of drug-susceptible tuberculosis (TB) without compromising the safety of patients. METHODS: We performed a systematic review of prospective clinical studies including adults with pulmonary and extrapulmonary TB receiving rifampicin doses above 10 mg/kg/day. We extracted the data on overall adverse events (AE), hepatic AE, sputum culture conversion (SCC) at week 8, recurrence, mortality, and pharmacokinetics. We performed a Bayesian network meta-analysis (NMA) using a random-effects model. RESULTS: In 19 studies, 2033 out of 3654 participants received rifampicin doses higher than 10 mg/kg/day. The NMA showed an increased risk of overall and hepatic AE for the 40 mg/kg/day dose (risk ratio [RR] 4.8, 95% credibility interval [CrI]: 1.1, 25, and 15.00; 95% CrI: 1.1, 58.0, respectively), but no other doses, including 50 mg/kg/day showed such an increase. Increasing doses improved sputum culture conversion at week 8 (RR 1.3, 95% CrI: 1.1, 1.7 for SCC with 35 mg/kg/day). CONCLUSIONS: Optimal doses of rifampicin may be between 25 and 35 mg/kg/day, but should be tailored at the individual or, at least, at the population level.
引用
- Espinosa-Pereiro J, Aguiar A, Nara E, et al. Safety, Efficacy, and Pharmacokinetics of Daily Optimized Doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis. Clin Infect Dis. 2025. PMID: 39792625. doi:10.1093/cid/ciaf003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。